MRSA/MRSE - VISA/GISA/VRSA - PRP - VRE: Emerging gram-positive pathogens and their mechanisms of resistance, prevalence and clinical consequence;MRSA/MRSE - VISA/GISA/VRSA - PRP - VRE: Aktuelle gram-positive problemkeime und ihre resistenzmechanismen, prävalenz und klinische konsequenz

Wiener Medizinische Wochenschrift

Volumn 153, Issue 7-8, 2003, Pages 144-147

  Apfalter, Petra ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

MRSA MRSE; PRP; VISA GISA VRSA; VRE

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; GLYCOPEPTIDE; IMIPENEM; LINEZOLID; MEROPENEM; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN; TEICOPLANIN; TICARCILLIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AUSTRIA; BACTERIAL INFECTION; ENTEROCOCCUS CASSELIFLAVUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ENTEROCOCCUS GALLINARUM; GENERAL HOSPITAL; GRAM POSITIVE BACTERIUM; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; PENICILLIN RESISTANCE; REVIEW; STREPTOCOCCUS PNEUMONIAE;

EID: 0038752803     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1563-258X.2003.03014.x     Document Type: Review

References (26)

1. Arthur M, Quintiliani R: Regulaiton of VanA- and VanB-type glycopeptide resistance in enterococci. Antimicrob Agents Chemother 2001;45:375-381.
2. Barber M: Methicillin-resistent staphylococci. J Clin Pathol 1961;14:385-393.
3. Biavasco F, Vignaroli C, Lazzarini R, Varaldo PE: Glycopeptide susceptibility profiles of Staphylococcus haemolyticus bloodstream isolates. Antimicrob Agents Chemother 2000;44:3122-3126.
4. CDC. Staphylococcus aureus resistant to Vancomycin - United States. 2002. MMWR 2002;51:565-7.
5. Cetinkaya Y, Falk P, Mayhall CG: Vancomycin-resistant enterococci. Clin Microbiol Rev 2000;13:686-707.
6. Chambers HF: Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin Microbiol Rev 1997;10:781-791.
7. Eliopoulos GM, Wennersten CB, Gold HS: Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin. Antimicrob Agents Chemother 1998;42:1088-1092.
8. Gold HS (2001) Vancomycin-resistant enterococci: mechanisms and clinical observations. Clin Infect Dis 33:210-219
9. Gonzales RD, Schreckenberger PC, Graham AB, Kelkar SK. DenBesten K, Quinn JP: Infections due to vancomycin-resistant Enterococcus faecium resistant to Linezolid. Lancet 2001;357:1179.
10. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC: Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-136. http.//www.rockefeller.edu/pubinfo/tomasz042500.nr.htm
11. Jorgensen JH, Ferraro MJ: Antimicrobial susceptibility testing: special needs for fastidious organisms and difficult-to-detect resistance mechanisms. Clin Infect Dis 2000;30:799-808.
12. Lowy FD (1998) Staphylococcus aureus infection. N Engl J Med 339:520-532
13. Mellmann A, Orth D, Dierich MP, Allerberger F, Klare I, Witte W: Nosocomial cross transmission as a primary cause of vancomycin-resistant enterococci in Austria. J Hosp Infect 2000;44:281-287.
14. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing: eleventh informational supplement M100-S11. Vol 21. No1. Wayne, Pennsylvania: National Committee for Clinical Laboratory Standards 2001.
15. Pittet D, Hugonnet S, Harborth S, Mourouga P, Sauvan V. Touveneau S: Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Lancet 2000;356:1307-1312.
16. Schrag SJ, Beall B, Dowell SF: Limiting the spread of resistant pneumococci: biological and epidemiologic evidence for the effectiveness of alternative intervention. Clin Microbiol Rev 2000;13:588-601.
17. Schwalbe RS, Stapleton JT, Gilligan PH: Emergence of vancomycin resistance in coagulasenegative staphylococci. N Engl J Med 1987;316:927-931.
18. Simon C, Stille W: Antibiotika-Therapie in Klinik und Praxis. Stuttgart, Schattauer, 2001.
19. Smith AM, Klugmann KP: Alterations in PBP 1A essential for high-level penicillin resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 1998;42:1329-1333.
20. Tenover FC, Biddle JW, Lancaster MV: Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001;2:327-333.
21. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, Moellering RC, Ferraro MJ: Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001;358:207-208.
22. Uttley AH, George RC, Naidoo J (1989) High-level vancomycin-resistant enterococci.
23. Wielders CLC, Vriens MR, Brisse S, de Graaf-Miltenburg LAM, Troelstra A, Fleer A, et al: Evidence for in-vivo transfer of mecA DNA between strains of Staphylococcus aureus. Lancet 2001;357:1674-1675.
24. Vancomycin-resistant Staphylococcus aureus - Pennsylvania, 2002. United States, 2002. MMWR 2002;51:902.
25. Wimmer M, Aspöck C, Pasching E, Wolf D, Rotter M, Hirschl AM: Heterogene Vancomycin-Resistenz bei Methicillin-resistenten Stämmen von Staphylococcus aureus. Abstract, 27. Jahrestagung der Österreichischen Gesellschaft für Hygiene, Mikrobiologie und Präventivmedizin, Goldegg, Salzburg, 2000.
26. Wu S, Piscitelli C, deLencastre H. Tomasz A: Tracking the evolutionary origin of the methicillin resistance gene: cloning and sequencing of a homologue of mecA from a methicillin susceptible strain of Staphylococcus sciuri. Microb Drug Resistance 1996;2:435-441.